CBIO Price Chart
Loading chart...
50 DMA150 DMA200 DMA
CBIOCrescent Biopharma, Inc.
$11.05
Financials
AVOID
Investment Thesis
CBIO is a market laggard (RS 12/99, Top 88%) with declining fundamentals. avoid chasing - protect capital. Smart traders skip this one until the setup improves.
Weak relative strength + ordinary growth = Pass
Key Takeaways
- Earnings weak
- RS 12 - market laggard
- No base pattern
- Wait & watch
Earnings Momentum
Earnings Declining
Price Structure
Broken StructurePrice
$11.05
→
50 DMA
$12.77
✓→
100 DMA
$12.74
→
150 DMA
$13.16
→
200 DMA
$15.54
Alignment Score: 1/4
LEADERSHIP TEST FAILED
RS Rating 12/99 is in Bottom 12% of market. Minervini target: Top 20% (RS 80+)
Why Not BUY Yet?
RS Rating
12 (Top 88%)→>80 (Top 20%)
EPS Growth
-8442%→>25% Qtr YoY
Pattern
No base forming→VCP or constructive base
Trend
Weak Downtrend→Above 200 DMA
Breakout Status
-77.4% below entry ($49.00)→Price above breakout entry
What Would Change Our Mind?
To turn bullish on CBIO, we need:
- RS Rating: >80 (Top 20%)(currently 12 (Top 88%))
- EPS Growth: >25% Qtr YoY(currently -8442%)
- Pattern: VCP or constructive base(currently No base forming)
- Trend: Above 200 DMA(currently Weak Downtrend)
- Breakout Status: Price above breakout entry(currently -77.4% below entry ($49.00))
- Breakout Recovery: Price recovers above $49.00(currently -77.4% below entry)
Twin Engines Dashboard
Technical Health
RS Rating
12/99
Top 88% (Need 80+)
Trend
Weak Downtrend
Below 200 DMA
RSI (14)
37
WEAK
VCP Setup
COOL
Score: 3/9
Volume
318K
+124% vs avg
From Entry
-77.4%
$49.00
Fundamental Horsepower
EPS Qtr YoY
-8442%
Declining
EPS 3Y CAGR
N/A
Annual Earnings
Revenue Qtr
N/A
DECLINING
F-Score
1/9
Piotroski Quality
ROE
-6%
Return on Equity
EPS Rank
0/99
Percentile
Trade Plan
Breakout FailedEntry Price$49.00Breakout price
Current Loss-77.4%Below entry
Stop Was$45.08Should have exited
If/Then Playbook
IF: RS Rating improves to >80
THEN: Re-evaluate for WATCHLIST
IF: Price closes below 200 DMA
THEN: Remove from radar entirely
IF: EPS growth accelerates to >40% next quarter
THEN: Reassess as potential turnaround
Key Price Levels
Resistance
- 20 DMA$11.80+6.8%
- 50 DMA$12.77+15.6%
- 200 DMA$15.54+40.6%
Current$11.05
Support
- 52W Low$9.81-11.2%
More CBIO Analysis
Frequently Asked Questions
Is CBIO stock a buy now?
CBIO is a market laggard (RS 12/99, Top 88%) with declining fundamentals. avoid chasing - protect capital. Smart traders skip this one until the setup improves.
What is the buy point for CBIO?
CBIO's breakout at $49.00 has failed (now -77.4% below entry). The setup is no longer valid — wait for a new base pattern to form.
What is CBIO's RS Rating?
CBIO has an RS Rating of 12/99, meaning it's in the Top 88% of all stocks for relative price performance over the past 12 months. Minervini recommends RS 80+ for momentum trades.
Important Disclosure: This analysis is for educational and informational purposes only. Technical and fundamental indicators are based on historical data and do not guarantee future performance. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.